Comparative Pharmacology
Head-to-head clinical analysis: LUMENHANCE versus TESLASCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMENHANCE versus TESLASCAN.
LUMENHANCE vs TESLASCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LUMENHANCE is a contrast agent that increases signal intensity in magnetic resonance imaging by shortening T1 relaxation time, enhancing tissue visualization.
Teslascan is a manganese-based paramagnetic contrast agent that enhances T1-weighted magnetic resonance imaging (MRI). Manganese ions shorten the T1 relaxation time of protons, increasing signal intensity in tissues where it accumulates.
1 mg intravenously once daily
0.1 mL/kg (0.1 mmol/kg) intravenous bolus injection.
None Documented
None Documented
Terminal elimination half-life is 8–10 hours in healthy adults; half-life may increase up to 15 hours in moderate hepatic impairment, requiring dose adjustment.
Terminal elimination half-life is 6.2 hours in patients with normal renal function (CrCl > 60 mL/min). In patients with moderate renal impairment (CrCl 30-60 mL/min), half-life increases to 9.5 hours; in severe impairment (CrCl < 30 mL/min), half-life exceeds 15 hours.
LUMENHANCE is primarily eliminated via renal excretion (70% unchanged) and biliary/fecal excretion (25% as metabolites). Approximately 5% is eliminated via other routes.
70% renal (unchanged drug), 30% fecal (biliary excretion).
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent